Comments on: Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

Comments on: Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia https://www.novumpr.nl/2019/10/22/vertex-announces-reimbursement-of-cystic-fibrosis-medicines-symdeko-tezacaftor-ivacaftor-and-ivacaftor-for-eligible-patients-ages-12-and-older-and-orkambi-lumacaftor-ivacaftor-i/?utm_source=rss&utm_medium=rss&utm_campaign=vertex-announces-reimbursement-of-cystic-fibrosis-medicines-symdeko-tezacaftor-ivacaftor-and-ivacaftor-for-eligible-patients-ages-12-and-older-and-orkambi-lumacaftor-ivacaftor-i NovumPR press releases Tue, 22 Oct 2019 13:20:00 +0000 hourly 1 https://wordpress.org/?v=6.8.3